Bristol-Myers Squibb Company (BMY) Saturday said an experimental drug showed positive results in patients suffering from melanoma, kidney cancer and lung cancer in a preliminary clinical trial.
Results of the Phase-I study on anti-PD-1 or BMS-936558 in patients with previously-treated non small-cell lung cancer, metastatic melanoma and renal cell carcinoma were encouraging as they showed improvement in patients. The clinical trial added to the understanding of the potential of immuno-oncology as a therapeutic approach in the treatment of cancer, the pharmaceutical firm said.
"Immuno-oncology is a prioritized area of research and development at Bristol-Myers Squibb and we plan to initiate registrational studies for anti-PD-1 in non small-cell lung cancer and renal cell carcinoma this year and late 2012, early 2013 for metastatic melanoma," Brian Daniels, senior vice president of Global Development and Medical Affairs t Bristol-Myers Squibb, said.
Anti-PD-1 is a fully-human antibody that targets the inhibitory receptor expressed on activated T-cells called PD-1 or programmed death-1.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org